6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors

US7820662B2 · kind B2 · utility

Assignee

• OSI Pharmaceuticals, LLC · US

Inventors

• Lee D. Arnold · Rancho Santa Fe, US
• Cara Cesario · Mishawaka, US
• Heather R. Coate · San Diego, US
• Andrew Philip Crew · North Babylon, US
• Hanqing Dong · Madison, US
• Kenneth Foreman · Syosset, US
• Ayako Honda · Cambridge, US
• Radoslaw Laufer · Oakville, CA
• An-Hu Li · New York, US
• Kristen Michelle Mulvihill · Northport, US
• Mark J. Mulvihill · Melville, US
• Anthony Nigro · Westwood, US
• Bijoy Panicker · Holbrook, US
• Arno G. Steinig · East Northport, US
• Yingchuan Sun · Cambridge, US
• Quinghua Weng · West Islip, US
• Douglas S. Werner · West Palm Beach, US
• Michael J. Wyle · Hempstead, US
• Tao Zhang · Waltham, US

Key dates

• Filing date: Oct 3, 2008
• Grant date: Oct 26, 2010
• Expiry date: Oct 3, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formulaand pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.